MX362129B - Modulacion del crecimiento de bifidobacterias mediante el uso de una combinacion de oligosacaridos que se encuentran en la leche humana. - Google Patents

Modulacion del crecimiento de bifidobacterias mediante el uso de una combinacion de oligosacaridos que se encuentran en la leche humana.

Info

Publication number
MX362129B
MX362129B MX2014008513A MX2014008513A MX362129B MX 362129 B MX362129 B MX 362129B MX 2014008513 A MX2014008513 A MX 2014008513A MX 2014008513 A MX2014008513 A MX 2014008513A MX 362129 B MX362129 B MX 362129B
Authority
MX
Mexico
Prior art keywords
oligosacarids
bifidobacteria
modulation
growth
found
Prior art date
Application number
MX2014008513A
Other languages
English (en)
Inventor
Curtis Frantz David
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45809349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX362129(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX362129B publication Critical patent/MX362129B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pediatric Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dairy Products (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una formulación líquida o seca de prebióticos para la administración oral a un humano, caracterizad porque comprende a) 0.5-2 mg/ml de 2´-fucosilactosa, 1-4 mg/ml de 3´-sialilactosa y 0.5-2 mg/ml de 6´-sialilactosa, cuando dicho formulación es líquida, o b) al menos 0.4% del peso de 6´-sialilactosa, cuando dicha formulación es un polvo seco.
MX2014008513A 2011-02-10 2012-02-03 Modulacion del crecimiento de bifidobacterias mediante el uso de una combinacion de oligosacaridos que se encuentran en la leche humana. MX362129B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161441451P 2011-02-10 2011-02-10
PCT/IB2012/050511 WO2012107865A2 (en) 2011-02-10 2012-02-03 Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk

Publications (1)

Publication Number Publication Date
MX362129B true MX362129B (es) 2019-01-07

Family

ID=45809349

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014008513A MX362129B (es) 2011-02-10 2012-02-03 Modulacion del crecimiento de bifidobacterias mediante el uso de una combinacion de oligosacaridos que se encuentran en la leche humana.
MX2013009087A MX345413B (es) 2011-02-10 2012-02-03 Modulacion del crecimiento de bifidobacterias mediante el uso de una combinacion de oligosacaridos que se encuentran en la leche humana.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013009087A MX345413B (es) 2011-02-10 2012-02-03 Modulacion del crecimiento de bifidobacterias mediante el uso de una combinacion de oligosacaridos que se encuentran en la leche humana.

Country Status (19)

Country Link
US (3) US20140371173A1 (es)
EP (2) EP2672844B2 (es)
CN (2) CN103347405A (es)
AU (1) AU2012215042B2 (es)
BR (1) BR112013020108A2 (es)
CA (1) CA2825697A1 (es)
CL (1) CL2013002210A1 (es)
ES (2) ES2527200T5 (es)
IL (1) IL227487A (es)
MX (2) MX362129B (es)
MY (1) MY161034A (es)
PH (1) PH12013501501A1 (es)
PL (1) PL2672844T3 (es)
PT (1) PT2672844E (es)
RU (1) RU2586928C2 (es)
SG (1) SG192095A1 (es)
TW (1) TW201244640A (es)
WO (1) WO2012107865A2 (es)
ZA (1) ZA201306751B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2825697A1 (en) 2011-02-10 2012-08-16 Nestec S.A. Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
EP2734049B1 (en) 2011-06-20 2018-05-02 H.J. Heinz Company Brands LLC Probiotic compositions and methods
WO2013154725A1 (en) * 2012-04-13 2013-10-17 Trustees Of Boston College Prebiotic compositions and methods of use
EP2708145B1 (en) 2012-09-14 2016-05-04 Abbott Laboratories Nutritional compositions for use in methods for modulating corticosterone levels in psychologically stressed individuals
CN113331426A (zh) 2014-04-08 2021-09-03 雅培公司 使用人乳寡糖增强对病原体的粘膜先天免疫反应和/或检测的方法
EP3209308B1 (en) * 2014-10-24 2022-08-03 Evolve Biosystems Inc. Activated bifidobacteria and methods of use thereof
WO2016086151A1 (en) * 2014-11-26 2016-06-02 Abbott Laboratories Infant formula with rrr-alpha-tocopherol, 2'-fucosyllactose, and a probiotic
CN106998774A (zh) * 2014-11-26 2017-08-01 雅培制药有限公司 包含人乳低聚糖、多不饱和脂肪酸、核苷酸以及叶黄素的婴儿配方
US10835544B2 (en) 2014-12-08 2020-11-17 Glycom A/S Synthetic composition for regulating satiety
US10987368B2 (en) 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
CN107106584A (zh) 2014-12-08 2017-08-29 格礼卡姆股份公司 用于治疗代谢障碍的合成组合物
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
ES3004085T3 (en) 2015-03-05 2025-03-11 Nestle Sa Compositions for use in improving stool consistency or frequency in infants or young children
EP3368047B1 (en) 2015-10-28 2023-04-26 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
US10835545B2 (en) 2015-10-28 2020-11-17 Glycom A/S Synthetic composition and method for modulating brain function and behaviour
EP3389668A4 (en) * 2015-12-15 2019-08-21 Glycom A/S MIXTURE OF HMOS
KR20230006028A (ko) 2016-06-21 2023-01-10 아를라 푸즈 에이엠비에이 우유 단백질 및 우유 당류를 함유하는 개선된 영양 제품의 제조 방법 및 상기 방법에 의해 수득된 제품
SG10202100843TA (en) * 2016-07-28 2021-03-30 Fonterra Cooperative Group Ltd Dairy product and process
US11260088B2 (en) 2017-06-21 2022-03-01 Abbott Laboratories Methods for increasing growth of beneficial bacteria in the gastrointestinal tract
BR112020010843A2 (pt) * 2017-11-30 2020-11-10 Glycom A/S oligossacarídeos do leite humano e composições sintéticas desses para modulação da microbiota
CN113950247A (zh) * 2019-06-05 2022-01-18 森永乳业株式会社 组合物
JP7474596B2 (ja) * 2020-01-20 2024-04-25 森永乳業株式会社 新規ビフィドバクテリウム属細菌、および当該細菌を含む組成物、並びに当該細菌の増殖促進用の組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260280A (en) 1989-02-07 1993-11-09 Snow Brand Milk Products Co., Ltd. Bacterial toxin neutralizer
EP1255449B2 (en) † 2000-02-17 2016-06-08 Nestec S.A. Nutritional formulation containing prebiotic substances
WO2001060246A2 (en) * 2000-02-18 2001-08-23 Argose, Inc. Multivariate analysis of green to ultraviolet spectra of cell and tissue samples
US6913778B2 (en) 2001-12-21 2005-07-05 Wyeth Infant formula compositions comprising increased amounts of alpha-lactalbumin
US7867541B2 (en) * 2003-04-14 2011-01-11 Mead Johnson Nutrition Company Compositions and methods of formulation for enteral formulas containing sialic acid
PL1638416T3 (pl) 2003-06-23 2013-09-30 Nestec Sa Zastosowanie żywnościowego preparatu do optymalizowania działania bariery jelitowej
EP1689348B1 (en) † 2003-12-05 2013-05-15 Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
DK1951060T3 (da) 2005-11-04 2018-01-29 Arla Foods Amba Koncentrat afledt af et mælkeprodukt beriget med naturligt forekommende sialyllactose og en fremgangsmåde til fremstilling deraf
WO2007114683A1 (en) * 2006-03-30 2007-10-11 N.V. Nutricia Milk oligosaccharides for stimulating the immune system
EP2060257A1 (en) 2007-11-08 2009-05-20 Nestec S.A. Prevention and treatment of secondary infections following viral infection
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
NL2001377C2 (nl) 2008-03-14 2009-09-15 Friesland Brands Bv Werkwijze voor het isoleren van siaalzuur bevattende oligosachariden, alsmede de hiermee verkrijgbare siaalzuur bevattende oligosachariden bevatttende samenstellingen.
WO2011012655A1 (en) * 2009-07-31 2011-02-03 Nestec S.A. Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients
NL2004200C2 (en) * 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides in weight management.
WO2011136647A1 (en) * 2010-04-27 2011-11-03 N.V. Nutricia Use of 6'-sialyl lactose in infant and toddler nutrition
SG191798A1 (en) * 2010-12-31 2013-08-30 Abbott Lab Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
CA2825697A1 (en) 2011-02-10 2012-08-16 Nestec S.A. Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk

Also Published As

Publication number Publication date
EP2672844B2 (en) 2022-10-05
MX345413B (es) 2017-01-27
IL227487A (en) 2015-10-29
SG192095A1 (en) 2013-08-30
EP2672844A2 (en) 2013-12-18
WO2012107865A2 (en) 2012-08-16
EP2792252A2 (en) 2014-10-22
ZA201306751B (en) 2015-05-27
MX2013009087A (es) 2013-09-13
PH12013501501A1 (en) 2019-10-07
AU2012215042B2 (en) 2016-01-14
CL2013002210A1 (es) 2014-01-10
CN104126749A (zh) 2014-11-05
TW201244640A (en) 2012-11-16
ES2692533T3 (es) 2018-12-04
EP2672844B1 (en) 2014-11-19
RU2013141449A (ru) 2015-03-20
ES2527200T5 (es) 2022-12-29
US20140371173A1 (en) 2014-12-18
US20150141367A1 (en) 2015-05-21
EP2792252B1 (en) 2018-09-12
IL227487A0 (en) 2013-09-30
WO2012107865A3 (en) 2012-11-01
PL2672844T3 (pl) 2015-04-30
RU2586928C2 (ru) 2016-06-10
CA2825697A1 (en) 2012-08-16
MY161034A (en) 2017-04-14
CN103347405A (zh) 2013-10-09
PT2672844E (pt) 2015-02-04
EP2792252A3 (en) 2015-03-25
ES2527200T3 (es) 2015-01-21
BR112013020108A2 (pt) 2017-06-13
US20120208782A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
MX362129B (es) Modulacion del crecimiento de bifidobacterias mediante el uso de una combinacion de oligosacaridos que se encuentran en la leche humana.
BR112013008005A2 (pt) composição farmacêutica kpiquida pronta para uso para adminidtração parental a um indivíduo
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
BR112013022495A2 (pt) formulação farmacêutica aquosa de tapentadol para administração oral
IN2014DN09571A (es)
AR098882A1 (es) Composición dentífrica que comprende óxido de zinc y citrato de zinc
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
MX2015016456A (es) Composicion farmaceutica, preparacion y sus usos.
UY33472A (es) ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
GT201200307A (es) NUEVOS DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENÉRGICOS ß2 Y COMO ANTAGONISTAS MUSCARÍNICOS M3
BR112012019997A2 (pt) composições de cuidado oral
BR112015011430A2 (pt) composição para liberação imediata e prolongada
DOP2015000145A (es) NUEVOS DERIVADOS CARBAMATO DE CICLOHEXILO Y QUINUCLIDINILO QUE TIENEN ACTIVIDAD COMO AGONISTAS ß2 ADRENÉRGICOS Y COMO ANTAGONISTAS MUSCARÍNICOS M3
MX2017006812A (es) Composición farmacéutica, preparación y usos de la misma.
MX376337B (es) Uso de inositoles fosfato para la fabricación de un medicamento para el tratamiento y/o prevención de una enfermedad asociada al fallo renal en un sujeto que padece fallo renal.
BR112013002714A2 (pt) forma de dosagem farmacêutica compreendendo 6-fluor-(n-metil- ou n,n-dimetil)-4-fenil-4,9-di-hidro-3h-espiro[ciclo-hexano-1,1-pirano[3,4,b]indol]-4-amina
BR112015014092A2 (pt) administração oral transmucosal de acetato de glatirâmer
BR112013026933A2 (pt) uso de uma combinação de pelo menos um carotenoide
CL2013003588A1 (es) Composicion farmaceutica en forma de suspension oral que comprende como principio activo una fraccion de flavonoide y como excipiente goma de xantano en la cantidad de 0,30 %p/p a 0,60 %p/p; uso para el tratamiento de la insuficiencia venosa.
BR112015010651A2 (pt) composição antiparasitária de amplo espectro de nitazoxanida, probióticos e prebióticos
BR112013025610A2 (pt) uso de um metapneumovírus aviário vivo, e, composição farmacêutica
ES2636783T3 (es) Producto dietético destinado a ser administrado a largo plazo a personas obesas operadas en cirugía bariátrica
MX2022000625A (es) Composicion farmaceutica de temozolomida.
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida